Superworth

Denali Therapeutics EPS DNLI

Diluted earnings per share by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
−$2.84
Latest quarter, Q2 FY26
−$0.68
Fiscal year 2025
−$2.97

Denali Therapeutics' earnings per share was −$2.84 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.68.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$2.97n/a
FY2024−$2.57n/a
FY2023−$1.08n/a
FY2022−$2.59n/a
FY2021−$2.39−824%
FY2020$0.33n/a
FY2019−$2.06n/a
FY2018−$0.41n/a
FY2017−$7.53n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.68n/a−$2.84
Q1 FY26−$0.69n/a−$2.88
Q4 FY25−$0.73n/a−$2.97
Q3 FY25−$0.74n/a−$2.91
Q2 FY25−$0.72n/a−$2.80
Q1 FY25−$0.78n/a−$2.67
Q4 FY24−$0.67n/a−$2.57
Q3 FY24−$0.63n/a−$2.76
Q2 FY24−$0.59−145%−$2.85
Q1 FY24−$0.68n/a−$0.96
Q4 FY23−$0.86n/a−$1.08
Q3 FY23−$0.72n/a−$0.96

Against its peers

Companies in Biotechnology nearest Denali Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
DNLIDenali Therapeutics−$2.84
ADMAAdma Biologics$0.70−18% a year
VCELVericel$0.46+283% a year
KRYSKrystal Biotech$7.98+62% a year
MGTXMeiraGTx$0.71
RGENRepligen$0.73
TECHBIO-TECHNE$1.15+150% a year
HALOHalozyme Therapeutics$3.35−23% a year
NBIXNeurocrine Biosciences$6.82+102% a year
EXELExelixis$3.18+53% a year
INCYIncyte$7.85+78% a year
Peer median$2.17

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Denali Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.